Skip to main content
ARDELYX, INC. logo

ARDELYX, INC. — Investor Relations & Filings

Ticker · ARDX ISIN · US0396971071 LEI · 549300F542QR4SXHCY32 US Manufacturing
Open in API
Filings indexed 1,078 across all filing types
Latest filing 2017-01-09 Regulatory Filings
Country US United States of America
Listing US ARDX

About ARDELYX, INC.

https://www.ardelyx.com/

Ardelyx, Inc. is a biopharmaceutical company that discovers, develops, and commercializes first-in-class medicines to address unmet medical needs. The company's primary therapeutic areas of focus are cardiorenal and gastrointestinal diseases. Its key commercial product is XPHOZAH® (tenapanor), a novel mechanism therapy for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Ardelyx also develops treatments for Irritable Bowel Syndrome with Constipation (IBS-C), aiming to advance patient care through its portfolio of innovative therapies.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K, a current report filed with the SEC to announce specific events. It includes an Item 2.02 Results of Operations and Financial Condition, which provides a brief update on cash and cash equivalents as of December 31, 2016, but does not contain detailed financial statements or comprehensive financial analysis. It also includes Item 7.01 Regulation FD Disclosure, attaching a corporate presentation as Exhibit 99.1. The document is relatively short (3145 characters) and primarily serves as an announcement of financial condition and a corporate presentation rather than a full financial report. According to the rules, such a document is best classified as a Regulatory Filing (RNS) because it does not contain substantive financial data or detailed financial reports, and it is not a full earnings release or interim report. The corporate presentation attached is also not the report itself but an exhibit to the filing. Therefore, the appropriate classification is Regulatory Filings (RNS).
2017-01-09 English
FORM 4
Director's Dealing
2016-12-21 English
FORM 3
Director's Dealing
2016-12-17 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated December 1, 2016, reporting a change in the company's management: appointment of Bryan Shaw as Chief Accounting Officer and changes in roles of other officers. The content focuses on management changes, compensation details, and background of the new appointee. There are no financial statements or earnings data, nor is it an announcement of a report publication. The document fits the category of Board/Management Information (MANG) as it announces changes in senior management positions.
2016-12-07 English
FORM 4
Director's Dealing
2016-11-16 English
S-8
Regulatory Filings Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans. It includes detailed information about the securities to be registered, indemnification provisions, and references to other SEC filings such as 10-K, 10-Q, and 8-K. It is not an annual report, earnings release, or any other financial report but a registration statement related to capital raising through employee stock plans. This type of filing is best classified under Regulatory Filings (RNS) as it does not fit into other specific categories and is a regulatory compliance document.
2016-11-10 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.